# Eloralintide: 7 Things to Know About Lilly's Amylin Drug

**By TelosRX Editorial Team** · 2026-11-02

**Eloralintide is an investigational once-weekly injection from Eli Lilly that targets amylin receptors, not GLP-1. It's still in phase 3 trials and not FDA-approved. [TelosRX](https://telosrx.com) covers the seven facts worth knowing now.**

Searches for eloralintide jumped this fall. That's no accident. Lilly published phase 2 results in late 2025, then showed combination data with tirzepatide in September 2026.

If you've seen the name and wondered what the fuss is about, here's the plain-English version. Seven points, with sources, and no hype.

## Eloralintide at a Glance

| Detail | What's known |
| --- | --- |
| Developer | Eli Lilly (code name LY3841136) |
| Drug class | Selective amylin receptor agonist |
| How it's given | Once-weekly injection under the skin |
| Studied for | Obesity and related conditions |
| Current stage | Phase 3 clinical trials |
| FDA status | Investigational; not FDA-approved |

## 1\. It Works on Amylin, Not GLP-1

Most weight-management drugs you've heard of target GLP-1. Eloralintide takes a different route. It mimics amylin, a hormone your pancreas releases alongside insulin after you eat.

Amylin helps with three things:

-   **Fullness:** it signals the brain that you've had enough.
-   **Slower stomach emptying:** food leaves the stomach more gradually.
-   **Post-meal glucagon:** it curbs a hormone that raises blood sugar.

Want the bigger picture? Our [amylin vs GLP-1 comparison](https://www.telosrx.com/blogs/glp1/amylin-vs-glp1-differences-comparison) explains how the two pathways differ.

## 2\. It's Built to Be Selective

Amylin receptors are close cousins of the calcitonin receptor. Some earlier amylin drugs hit both.

Eloralintide was designed to favor the amylin 1 receptor (AMY1R). The goal is fewer off-target effects at the calcitonin receptor. Whether that design translates into a meaningful clinical advantage is still being studied.

This selectivity is the main thing separating it from cagrilintide, Novo Nordisk's amylin analog. Our [guide to amylin analogs](https://www.telosrx.com/blogs/glp1/amylin-analogs-6-drugs-to-know) lines up all six drugs in the class.

## 3\. The Phase 2 Trial Showed Dose-Dependent Results

The key study was a 48-week, placebo-controlled phase 2 trial published in [The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(25\)02155-5/abstract) in late 2025. It enrolled 263 adults with obesity or overweight, without type 2 diabetes. Average starting weight was about 109 kg (240 lb).

Mean body-weight change at 48 weeks, as reported by Lilly:

| Dose arm | Mean weight change |
| --- | --- |
| 1 mg | −9.5% |
| 3 mg | −12.4% |
| 6 mg | −17.6% |
| 9 mg | −20.1% |
| 6→9 mg escalation | −19.9% |
| 3→6→9 mg escalation | −16.4% |
| Placebo | −0.4% |

These are trial averages, not predictions. Individual responses varied, and a phase 2 trial is too small to settle long-term safety.

## 4\. Nausea and Fatigue Were the Most Common Side Effects

The [trial abstract on PubMed](https://pubmed.ncbi.nlm.nih.gov/41207310/) lists nausea and fatigue as the most common adverse events. Rates swung a lot by dose and escalation schedule.

-   **Nausea:** 11% at 1 mg, 64% at a fixed 6 mg start, and 25% with the slowest 3→9 mg escalation. Placebo was 14%.
-   **Fatigue:** ranged from 0% at 1 mg to 46% in the 6→9 mg arm. Placebo was 12%.

One pattern stands out. Slower dose escalation was linked with less nausea. That's familiar from GLP-1 drugs, where gradual titration (step-by-step dose increases) is standard.

## 5\. Lilly Is Pairing It With Tirzepatide

Lilly calls the combination EloraTZP. It pairs eloralintide with tirzepatide, which already acts on GIP and GLP-1 receptors. The result targets three hormone pathways at once.

A 48-week phase 2b trial in adults with obesity and type 2 diabetes was presented at the European Association for the Study of Diabetes meeting in September 2026. Lilly reported substantial weight and A1C reductions. The company plans to start phase 3 trials of a co-formulation by the end of 2026.

Amylin-plus-incretin combos are a clear trend. Novo Nordisk is testing a similar idea with CagriSema. Our [CagriSema Q&A](https://www.telosrx.com/blogs/glp1/cagrisema-questions-answered) covers that one.

## 6\. Phase 3 Trials Are Running Now

Eloralintide has completed phase 1 and phase 2. Lilly is now running phase 3 trials of eloralintide on its own. Registered studies include obesity and overweight without type 2 diabetes, such as [NCT07321886](https://clinicaltrials.gov/study/NCT07321886).

Lilly has also said it's studying related conditions:

-   Obstructive sleep apnea
-   Knee osteoarthritis pain
-   Type 2 diabetes, in combination with tirzepatide

Phase 3 trials usually take years. No approval date has been announced, so consider any "launch date" you see online as speculation.

## 7\. You Can't Get It Outside a Trial

Eloralintide isn't FDA-approved. No pharmacy can legally dispense it, and it isn't available through compounding.

That hasn't stopped "research peptide" sellers from listing it. Those vials have no verified identity, purity, dose or sterility. The trial results above came from pharmaceutical-grade drug and close medical monitoring. A mystery vial offers neither.

The only legitimate way to receive eloralintide today is by enrolling in a clinical trial.

**Want a provider-supervised option you can start now?** Explore [tirzepatide at TelosRX](https://www.telosrx.com/pages/tirzepatide). Any prescription is subject to medical approval by a licensed provider after an asynchronous review of your intake. Compounded tirzepatide is not FDA-approved.

## How Eloralintide Compares to What's Available Now

| Medication | Main target | Status |
| --- | --- | --- |
| Eloralintide | Amylin receptor | Investigational (phase 3) |
| Cagrilintide | Amylin and calcitonin receptors | Investigational |
| Semaglutide | GLP-1 | FDA-approved brands available |
| Tirzepatide | GIP and GLP-1 | FDA-approved brands available |

For now, approved GLP-1 and GIP/GLP-1 medications are the established options. Amylin drugs may join them later, if phase 3 data and FDA review go well.

## Frequently Asked Questions

### What is eloralintide?

Eloralintide is an investigational once-weekly injection developed by Eli Lilly. It's a selective amylin receptor agonist, meaning it mimics amylin, a hormone that helps you feel full after eating. It's being studied for obesity and related conditions. It is not FDA-approved and is only available inside clinical trials.

### Is eloralintide a GLP-1?

No. Eloralintide works on amylin receptors, not GLP-1 receptors. Amylin and GLP-1 are separate hormones that both influence appetite and digestion after meals. Lilly is also testing eloralintide combined with tirzepatide, a GIP and GLP-1 medication, in a combination called EloraTZP that targets three hormone pathways.

### What were the eloralintide phase 2 results?

In a 48-week phase 2 trial of 263 adults published in The Lancet, mean weight change ranged from about 9.5% at 1 mg to 20.1% at 9 mg, versus 0.4% with placebo. These were averages, and individual results varied. Larger phase 3 trials are now testing efficacy and safety.

### What are the side effects of eloralintide?

Nausea and fatigue were the most common side effects in the phase 2 trial. Rates depended heavily on dose and how fast the dose was increased. Slower escalation was linked with less nausea. Long-term safety is still being studied in phase 3 trials, so the full side-effect profile isn't known yet.

### When will eloralintide be available?

No approval date has been announced. Eloralintide is in phase 3 trials, which typically take years to complete before an FDA submission. After submission, FDA review adds more time. Until approval, the only legitimate way to receive it is by enrolling in a clinical trial.

### Can I buy eloralintide online?

Not legitimately. Eloralintide isn't FDA-approved, so no licensed pharmacy can dispense it, and it isn't available through compounding. Sellers offering "research" vials provide no verified identity, dose, purity or sterility. If you want weight-management support now, talk with a licensed provider about approved options.

_TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** amylin agonist, eloralintide, eloralintide side effects, EloraTZP, listicle, weight management research

---

> Source: [Telos RX](https://www.telosrx.com/blogs/glp1/eloralintide-7-things-to-know)
